Advertisement
Home Tags Blood Disorders

Tag: Blood Disorders

For patients with severe β-thalassemia

Gene Therapy Found to Be Promising for β-Thalassemia

0
CD34+ cells transduced with BB305 vector lowered or eliminated need for red-cell transfusions
From 2011 to 2014

RBC, Plasma Transfusions Drop From 2011 to 2014

0
Red blood cell and plasma transfusions decreased, while platelet transfusions remained stable
Low serum sodium is associated with cognitive impairment and cognitive decline among community-dwelling older men

Low Serum Sodium Linked to Cognitive Decline in Older Men

0
126 to 140 mmol/L linked to increased odds of prevalent cognitive impairment, decline in older men
For patients with severe hereditary hemorrhagic telangiectasia-related bleeding

IV Bevacizumab Effective for Severe HHT-Related Bleeding

0
Drop in RBC transfusion requirements, epistaxis severity in hereditary hemorrhagic telangiectasia
Patients with myeloproliferative neoplasms (MPNs) have increased risk of arterial thrombosis and venous thrombosis across all age groups and MPN subtypes

Increased Risk of Thrombosis in Myeloproliferative Neoplasms

0
Higher rates of thrombosis compared to matched controls; risk highest at and soon after diagnosis

American Society of Hematology, Dec. 9-12

0
The 59th American Society of Hematology Annual Meeting and Exposition The annual meeting of the American Society of Hematology was held from Dec....
A new approach to gene therapy can restore immune cell types in infants with newly diagnosed X-linked severe combined immunodeficiency

ASH: New Approach to Gene Tx Restores Immune Cells in X-SCID

0
Efficient vector marking in bone marrow CD34+ cells, myeloid cells, B cells in newly diagnosed SCID
Plasma N-terminal pro-B-type natriuretic peptide levels are significantly lower for black than white individuals

NTproBNP Levels Are Significantly Lower in Blacks

0
Higher NTproBNP levels linked to increased risk of death; this association did not differ by race
Hemlibra (emicizumab-kxwh) has been approved by the U.S. Food and Drug Administration to prevent or reduce the frequency of bleeding episodes among hemophilia A patients with Factor VIII inhibitors.

FDA OKs Drug for Hemophilia A With Factor VIII Inhibitors

0
Weekly prophylactic treatment associated with substantial decrease in bleeding episodes
For patients with acute severe bleeding

Delay in Tranexamic Acid Administration Reduces Benefit

0
Survival benefit decreases by 10 percent for every 15-minute delay in treatment for severe bleeding